AMGN

Amgen Inc. Press Releases

$174.8
*  
0.79
0.45%
Get AMGN Alerts
*Delayed - data as of Aug. 4, 2015  -  Find a broker to begin trading AMGN now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

Amgen Announces Appointment Of Fred Hassan To Board Of Directors
7/30/2015 4:05:00 PM - PR Newswire
▼-0.34 % Price Change since this news event. The Volume Ratio is 1.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57
7/30/2015 4:01:00 PM - PR Newswire
▲1.81 % Price Change since this news event. The Volume Ratio is 1.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Announces 2015 Third Quarter Dividend
7/28/2015 5:46:00 PM - PR Newswire
▲1.09 % Price Change since this news event. The Volume Ratio is 1.71.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Announces Webcast of 2015 Second Quarter Financial Results
7/27/2015 4:01:00 PM - PR Newswire
▲5.59 % Price Change since this news event. The Volume Ratio is 3.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
7/24/2015 12:40:00 PM - PR Newswire
▲7.32 % Price Change since this news event. The Volume Ratio is 5.55.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Submits Supplemental New Drug Application For Kyprolis® (Carfilzomib) In Relapsed Multiple Myeloma
7/23/2015 9:00:00 AM - PR Newswire
▲5.75 % Price Change since this news event. The Volume Ratio is 0.7.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Biotechnology Sector Stocks Technical Coverage -- Amgen, Exelixis, XOMA Corp., Theravance, and NewLink Genetics
7/22/2015 9:22:00 AM - PR Newswire
▲7.54 % Price Change since this news event. The Volume Ratio is 0.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Commission Approves Amgen''s New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol
7/21/2015 7:02:00 AM - PR Newswire
▲6.36 % Price Change since this news event. The Volume Ratio is 1.09.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study Results In Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
7/16/2015 4:01:00 PM - PR Newswire
▲7.21 % Price Change since this news event. The Volume Ratio is 1.36.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714 at 16th International Coeliac Disease Symposium
6/22/2015 1:03:00 AM - PR Newswire
▲9.17 % Price Change since this news event. The Volume Ratio is 0.67.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Presents Open-Label Extension Data From Ongoing Phase 2 Study Of AMG 334 In The Prevention Of Episodic Migraine
6/19/2015 4:00:00 PM - PR Newswire
▲8.76 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Results From Phase 3 Trial Show Vectibix® (Panitumumab) Improves Overall Survival In Chemorefractory Wild-Type KRAS Metastatic Colorectal Cancer Versus Best Supportive Care
6/18/2015 4:01:00 PM - PR Newswire
▲9.17 % Price Change since this news event. The Volume Ratio is 2.16.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Kezar Life Sciences Closes $23M Series A Financing
6/16/2015 9:00:00 AM - PR Newswire


Amgen To Discuss Details Of Repatha™ (Evolocumab) Biologics License Application For The Treatment Of High Cholesterol
6/10/2015 8:00:00 AM - PR Newswire
▲13.12 % Price Change since this news event. The Volume Ratio is 3.03.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen To Present At The Goldman Sachs Global Healthcare Conference
6/8/2015 4:00:00 PM - PR Newswire
▲11.71 % Price Change since this news event. The Volume Ratio is 1.37.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease
6/5/2015 8:00:00 AM - PR Newswire
▲10.49 % Price Change since this news event. The Volume Ratio is 1.34.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab
6/2/2015 1:00:00 AM - PR Newswire
▲11.32 % Price Change since this news event. The Volume Ratio is 0.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors
6/1/2015 9:00:00 AM - PR Newswire
▲11.86 % Price Change since this news event. The Volume Ratio is 1.05.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Initiates Phase 3 Study Evaluating Once-Weekly Kyprolis® (carfilzomib) in Patients With Relapsed And Refractory Multiple Myeloma
5/31/2015 7:00:00 AM - PR Newswire
▲11.65 % Price Change since this news event. The Volume Ratio is 1.01.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA® (Pembrolizumab) In Patients With Head And Neck Cancer
5/29/2015 8:30:00 AM - PR Newswire
▲10.49 % Price Change since this news event. The Volume Ratio is 1.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease
5/29/2015 6:45:00 AM - PR Newswire
▲10.49 % Price Change since this news event. The Volume Ratio is 1.82.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen Launches Program To Further Advance Basic Biology Research
5/28/2015 4:00:00 PM - PR Newswire
▲11.09 % Price Change since this news event. The Volume Ratio is 1.84.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen To Present At The Jefferies 2015 Global Healthcare Conference
5/27/2015 4:30:00 PM - PR Newswire
▲8.95 % Price Change since this news event. The Volume Ratio is 1.81.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Amgen To Advance Understanding Of The Treatment Of Blood Cancers At 20th Congress of European Hematology Association (EHA)
5/27/2015 4:00:00 PM - PR Newswire
▲8.95 % Price Change since this news event. The Volume Ratio is 1.8.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day